Cooperative Study Group A for Hematology

Lenalidomide After Failure of Hypomethylating Agents in Myelodysplastic Syndrome

Role: collaborator

Comparison of Cy-Atg vs Flu-Atg for the Conditioning Therapy in Allo-HCT for Adult Aplastic Anemia

Role: lead

High Dose Daunorubicin Vs. Standard Dose Daunorubicin in Induction Treatment of AML

Role: lead

Two Cycles of PAD Combination by AHCT in MM

Role: lead

Conditioning Regimen Before Infusion of Allogeneic Hematopoietic Stem Cells

Role: lead

Using Fludarabine and Melphalan Conditioning Regimen for CLL,Lymphoma,Multiple Myeloma

Role: lead

Comparison of Cy-Atg Vs Cy-Flu-Atg for the Conditioning Therapy in Allo-HCT

Role: lead

Busulfan Plus Cyclophosphamide vs Fludarabine as a Conditioning Regimen

Role: lead

High Dose Dexamethasone Vs. Conventional Dose Prednisolone in Adult ITP

Role: lead

Helicobacter Pylori Immune Thrombocytopenic Purpura

Role: lead

Cyclophosphamide, Fludarabine and Antithymocyte Globulin Conditioning in Myelodysplastic Syndrome (MDS)

Role: lead

Reduced-intensity Conditioning Allogeneic Hematopoietic Cell Transplantation

Role: lead

Efficacy of Helicobacter Pylori Eradication, Anti-D and Danazol Combination in Steroid Dependant or Refractory Immune Thrombocytopenia (ITP)

Role: lead

Autologous Hematopoietic Cell Transplantation for Core-binding Factor (CBF) Acute Myeloid Leukemia (AML) in the First Complete Remission (CR1)

Role: lead

Idarubicin Versus High Dose Daunorubicin in Acute Myelogenous Leukemia (AML)

Role: lead

A Phase II Study of CODOX-M/ IVAC in Relapsed/Refractory ALL

Role: lead

FLAG+Ida With G-CSF Priming for Patients Younger Than 60 Years With Resistant AML

Role: lead

Biweekly Gemcitabine-Oxaliplatin and Dexamethasone for Relapsed/Refractory Malignant Lymphoma

Role: lead

Fludarabine and Cytarabine as Continuous Infusion Plus G-CSF Priming for Elderly Patients With Resistant AML

Role: lead